75 related articles for article (PubMed ID: 21340788)
21. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer genomic instability correlates with p53 frameshift mutations.
Sood AK; Skilling JS; Buller RE
Cancer Res; 1997 Mar; 57(6):1047-9. PubMed ID: 9067268
[TBL] [Abstract][Full Text] [Related]
23. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.
Brachman DG; Graves D; Vokes E; Beckett M; Haraf D; Montag A; Dunphy E; Mick R; Yandell D; Weichselbaum RR
Cancer Res; 1992 Sep; 52(17):4832-6. PubMed ID: 1324797
[TBL] [Abstract][Full Text] [Related]
24. SSCP and Sequence Analysis of p53 Mutations in Ovarian Tumors.
Sood AK; Buller RE
Methods Mol Med; 2001; 39():323-8. PubMed ID: 21340787
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
27. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
28. An abundance of p53 null mutations in ovarian carcinoma.
Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
[TBL] [Abstract][Full Text] [Related]
29. [Chromosome arm 17p13.3: could HIC1 be the one ?].
Chopin V; Leprince D
Med Sci (Paris); 2006 Jan; 22(1):54-61. PubMed ID: 16386221
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer.
Lindahl T; Landberg G; Ahlgren J; Nordgren H; Norberg T; Klaar S; Holmberg L; Bergh J
Carcinogenesis; 2004 Mar; 25(3):375-80. PubMed ID: 14633656
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer.
Ahrendt SA; Decker PA; Doffek K; Wang B; Xu L; Demeure MJ; Jen J; Sidransky D
Cancer Res; 2000 May; 60(9):2488-91. PubMed ID: 10811129
[TBL] [Abstract][Full Text] [Related]
32. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.
Shahedian B; Shi Y; Zou M; Farid NR
Mol Genet Metab; 2001 Feb; 72(2):155-63. PubMed ID: 11161841
[TBL] [Abstract][Full Text] [Related]
33. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.
Huang Y; Meltzer SJ; Yin J; Tong Y; Chang EH; Srivastava S; McDaniel T; Boynton RF; Zou ZQ
Cancer Res; 1993 Apr; 53(8):1889-94. PubMed ID: 8467510
[TBL] [Abstract][Full Text] [Related]
34. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.
Konishi N; Hiasa Y; Matsuda H; Tao M; Tsuzuki T; Hayashi I; Kitahori Y; Shiraishi T; Yatani R; Shimazaki J
Am J Pathol; 1995 Oct; 147(4):1112-22. PubMed ID: 7573356
[TBL] [Abstract][Full Text] [Related]
35. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
[TBL] [Abstract][Full Text] [Related]
36. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R
Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696
[TBL] [Abstract][Full Text] [Related]
37. p53 Adenovirus as Gene Therapy for Ovarian Cancer.
Carroll JL; Michael Mathis J; Bell MC; Santoso JT
Methods Mol Med; 2001; 39():783-92. PubMed ID: 21340840
[TBL] [Abstract][Full Text] [Related]
38. A frequent deletion polymorphism on chromosome 22q13 identified by representational difference analysis of ovarian cancer.
Lin H; Pizer ES; Morin PJ
Genomics; 2000 Nov; 69(3):391-4. PubMed ID: 11056057
[TBL] [Abstract][Full Text] [Related]
39. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
40. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
